MiR-16 mediates trastuzumab and lapatinib response in ErbB-2-positive breast and gastric cancer via its novel targets CCNJ and FUBP1

12
Sep
Date 12 septiembre, 2018

MiR-16 mediates trastuzumab and lapatinib response in ErbB-2-positive breast and gastric cancer via its novel targets CCNJ and FUBP1

Author maller
Ciudad Universitaria, Pabellón II 4º Piso CP: C1428EGA   |   Ciudad Autónoma de Buenos Aires, Argentina   |   Teléfonos: (+54-11) 4788-5755 o 528-58710 / Fax: 4788-5755